TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05399862

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17648 probiotic
Description: Lactobacillus reuteri DSM 17648 is a single-strain probiotic used as adjunct treatment in H.pylori infection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule with no microbial cell preparation
Study: NCT02557581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endurance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02482948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Leptospermum Honey (Medihoney)
Description: STudy agent to be applied to the wound daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase
Description: Study agent to be applied daily to the wound.
Study: NCT03870308

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional MRI
Description: A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
Study: NCT02981082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl Fumarate (DMF)
Description: Dimethyl Fumarate (DMF) is a prescription medicine used to treat relapsing multiple sclerosis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Sugar pill manufactured to mimic Dimethyl Fumarate (DMF)
Study: NCT02944552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicyclol tablet 25mg
Description: Patients in the low dose group administrated bicyclol tablet 25mg, one bicyclol blank analog tablet and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
Study: NCT04164654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loneliness Intervention
Description: 28 days of engagement with the Nod app, which consists of interactive exercises drawn from cognitive behavioral therapy (e.g behavioral activation and cognitive reframing exercises), positive psychology (e.g. acts of kindness), and mindful self-compassion programs (e.g. loving-kindness meditations)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Loneliness Intervention
Description: 28 days of engagement with the Nod app, which consists of interactive exercises drawn from cognitive behavioral therapy (e.g behavioral activation and cognitive reframing exercises), positive psychology (e.g. acts of kindness), and mindful self-compassion programs (e.g. loving-kindness meditations)
Study: NCT00722670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Woman-focused intervention
Description: Participants in this group received a four individual sessions of the woman-focused intervention, in addition to services that were part of their substance abuse treatment program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants in this group only received services that were part of their substance abuse treatment program
Study: NCT02944552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicyclol tablet 50mg
Description: Patients in the high dose group administrated bicyclol tablet 50mg and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyene phosphatidylcholine capsule 456mg
Description: Patients in the positive drug control group administrated polyene phosphatidylcholine capsules 456mg and two bicyclol blank analog tablets orally, three times daily for 4-8 weeks.
Study: NCT03511040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumenate Intraluminal Device
Description: Dilation of vasospastic intracranial vessels
Study: NCT02476812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Piggy Bank
Description: Already noted.
Study: NCT00708214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: BIBW 2992 at high and medium dosages

Intervention type: DRUG
Group type: OTHER
Intervention: BIBW 2992
Description: BIBW 2992 at high and medium dosages

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole at standard dosage

Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Letrozole at standard dosage
Study: NCT00107289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iobenguane I 131
Description: Patients receive a single dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) IV over 30 minutes to 4 hours or for 15 minutes for smaller patients on day 0. Patients undergo radiation dosimetry following the first dose of \^131I-MIBG to determine if a second dose can be safely administered. Some patients may receive a second dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) 6-8 weeks after the first dose if response is achieved and patients do not experience major toxicity. After blood radioactivity has fallen below 1 μCi/mL, patients may undergo autologous stem cell transplantation.~After completion of study treatment, patients are followed at 4-6 weeks after \^131I-MIBG administration and then every 3 months for up to 1 year.
Study: NCT04042116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Oral lucitanib will be administered once daily (QD). The dose will be 6 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.~Subjects will be allowed to intrapatient dose escalate in increments of 2 mg up to a total dose of 10 mg QD lucitanib if they meet the study specific clinical criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.~Subjects will be allowed to intrapatient dose escalate in increments of 2 mg up to a total dose of 10 mg QD lucitanib if they meet the study specific clinical criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.~Subjects will be allowed to intrapatient dose escalate in increments of 2 mg up to a total dose of 10 mg QD lucitanib if they meet the study specific clinical criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.~Subjects will be allowed to intrapatient dose escalate in increments of 2 mg up to a total dose of 10 mg QD lucitanib if they meet the study specific clinical criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV nivolumab 480 mg will be administered once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV nivolumab 480 mg will be administered once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV nivolumab 480 mg will be administered once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV nivolumab 480 mg will be administered once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV nivolumab 480 mg will be administered once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV nivolumab 480 mg will be administered once every 4 weeks.
Study: NCT03402256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: In addition to the SC interventions, participants in the Text Message condition received text messages. Participants received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Participants will receive messages targeting known predictors of alcohol abstinence and relapse, including (1) craving, (2) identification of high-risk situations, (3) identification of triggers, (4) stress level, (5) coping skills, and (5) quality of life. The text messages will include motivational messages and behavior-change techniques (e.g. coping with cravings and urges to drink, trigger identification, high-risk situation identification). Messages will encourage participants to continue with sobriety and focus on the success they have achieved so far.
Study: NCT01742299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Imatinib will be provided as 100 mg and 400 mg tablets taken orally once daily unless other wise instructed by investigator
Study: NCT02203552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline hydrochloride
Description: 100 mg bid given by mouth for 9 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo given by mouth for 9 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: The CES-D and STAI will be administrated weekly.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire administration
Description: The CES-D and STAI will be administrated weekly.
Study: NCT04466150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: open label biomarker study
Study: NCT02978625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Mammography
Description: Undergo PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given IT
Study: NCT04493060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study: NCT00946296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Iodide
Description: 8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.
Study: NCT03305523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocautery
Description: In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medical, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
Study: NCT02933801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201
Description: ODM-201 will be given at a dose of 600 mg BID orally on a continuous basis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given at a dose of 600 mg BID orally on a continuous basis.
Study: NCT02130284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predictive Low Glucose Management Feature in Insulin pump
Description: All subjects will undergo hypoglycemic induction at Visit 2 with target set to 65 mg/dL using the rate of change basal increase algorithm. Low Limit setting when PLGM ON is 65 mg/dL.
Study: NCT01160874

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography
Description: Sleep study monitoring

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Sleep study monitoring

Intervention type: OTHER
Group type: OTHER
Intervention: Maintenance Wakefulness Test
Description: Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.

Intervention type: OTHER
Group type: OTHER
Intervention: Maintenance Wakefulness Test
Description: Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintenance Wakefulness Test
Description: Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological evaluation
Description: Neuropsychological evaluation for cognitive functions study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: Neuropsychological evaluation for cognitive functions study

Intervention type: OTHER
Group type: OTHER
Intervention: Driving test on a simulator
Description: Driving simulator test during wich a camera register different parameters as the position of the vehicle.

Intervention type: OTHER
Group type: OTHER
Intervention: Driving test on a simulator
Description: Driving simulator test during wich a camera register different parameters as the position of the vehicle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving test on a simulator
Description: Driving simulator test during wich a camera register different parameters as the position of the vehicle.
Study: NCT01802684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Aflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)
Study: NCT03758365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Butyrate 0.1% Cream
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desonide 0.05% Cream
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Study: NCT00721019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-hour bedtime
Description: 10 days with sleep restricted only to a 5-hour bedtime period at night

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8.5-hour bedtimes
Description: 10 days with sleep allowed only during a 8.5-hour period at night
Study: NCT02623829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin
Description: 50 units of botulinum toxin diluted in 1ml of normal saline will be administered.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: 1ml of normal saline will be administered
Study: NCT02103088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual and urological intervention
Description: Sexual and urological intervention consisting of: i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
Study: NCT01530815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine Infusion
Description: Investigators and Caregivers will be blinded to either 0.9% Normal Saline or 0.5% Bupivicaine infusion between the mesh and abdominal wall
Study: NCT02711956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study: NCT02081521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community behaviour change campaign
Description: Community campaign targeting exclusive breastfeeding, handwashing with soap, and use of ORS and zinc to manage child diarrhoea. Includes a range of activities within the community (large events and small group sessions); clinic activities (ORS preparation), radio adverts.
Study: NCT04740021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP002
Description: 10 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 administered as IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 administered as IV infusion on Day 1, 2 and 3 of each 21-day cycle.
Study: NCT01681680

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Subjects will be given an oral dose of metformin once per day for two days.
Study: NCT06264102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Description: Training sessions took place twice a week for 45 minutes each over a period of 12 weeks. Each training included rhythmic exercises using the Jaques-Dalcroze Eurhythmics (JDE) method with piano accompaniment and electronically played music. Training sessions were conducted by a JDE specialist.~Exercises with the use of this method consist mainly in the repetition of preset musical sequences using body movements. In addition to the physical layer, the cognitive layer was equally important: while performing a given movement exercise, participants often had to focus in order to react appropriately to additional tasks, such as changes in sound pitch and rhythm of the piece.
Study: NCT02337439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Information Processing Training
Description: Computer exercises requiring identification of visual stimuli on computer screen and response with keyboard

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Training
Description: Commercially available educational software
Study: NCT03687684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 Tablets.
Study: NCT03604835

Intervention type: OTHER
Intervention: No Intervention
Description: Access to any treatment is through authorized commercial use or available expanded access programs only and not as a part of this DMP.

Intervention type: OTHER
Intervention: No Intervention
Description: Access to any treatment is through authorized commercial use or available expanded access programs only and not as a part of this DMP.
Study: NCT02519829

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl closure
Description: Total Hip Arthroplasty with monocryl closure of wound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl and Staple closure
Description: Total Hip Arthroplasty with vicryl and staple closure of wound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm dressing
Description: Total Hip Arthroplasty with monocryl closure of wound and tegaderm dressing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze dressing
Description: Total Hip Arthroplasty with vicryl and staple closure of wound and gauze dressing
Study: NCT02259556

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART30
Description: Cells will be infused 1 day after the completion of conditioning regimen.
Study: NCT01276782

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levothyroxine
Description: It is FDA approved drug for thyroid disease
Study: NCT02334059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine infusion plus placebo infusion of normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine plus magnesium
Description: Ketamine plus magnesium infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 placebo infusions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo infusions
Study: NCT02470039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 338 (GIPET I)
Description: Oral administered once daily in combination with metformin with or without DPP-4 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected s.c./subcutaneously (under the skin) once daily in combination with metformin with or without DPP-4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Administered once daily